礼来宣布穆峰达(替尔泊肽注射液)获得中国国家药品监督管理局(NMPA)批准成为首个且目前唯一用于治疗成人肥胖患者的中度至

智通财经
03 Jul
礼来宣布穆峰达(替尔泊肽注射液)获得中国国家药品监督管理局(NMPA)批准成为首个且目前唯一用于治疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停(OSA)的处方药。替尔泊肽可改善中度至重度阻塞性睡眠呼吸暂停肥胖成人患者的睡眠障碍。该适应症的使用需在控制饮食和增加运动基础上进行。。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10